As the demand for #assay data continues to grow and enabling technology allows us to generate huge datasets at impressive speeds, assay design is as critical as ever, writes @Brian…

“The world now knows that #diagnostics matter,” BioDot CEO Tony Lemmo said in a recent interview with @Jessie Yount of the Orange County Business Journal. “We, as a society, won’t go back…

It’s imperative that #diagnostics firms continue to expand their capacity for #COVID19 test production. BioDot CEO Tony Lemmo recently spoke with @360dx to discuss how this industry-wide expansion won’t be easy, but it is…

BioDot is helping customers unlock expanded #COVID19 antigen test production to enable schools and workplaces to conduct mass testing. Recent orders for BioDot equipment will translate into ~500m tests in the coming…

Congratulations to Calmark, keep up the great work! Calmark announces today that the product development of an LDH test for assessment (triage) of COVID-19 is proceeding according to plan; the…

Job Spec. European Field Support The Role BioDot Ltd, has a vacancy for a Field based support person to cover their European, Middle East, Russian and South African customer base….

Draper to Build on its Biosecurity Tool Development for IARPA TUESDAY, JULY 28, 2020 CAMBRIDGE, MA—Advances in gene editing technology and improved access via the web have substantially increased the…

Anthony V. Lemmo, CEO of BioDot discusses the demand for COVID-19 tests and the diagnostic manufacturing communities ability to scale-up production. To read the full article go to: https://www.barrons.com/articles/covid-19-test-demand-will-break-global-capacity-without-immediate-investment-51596223970  …

Authors Brianna Abbott, Elbert Wang and Denise Roland discuss COVID-19 antibody testing. After a rocky rollout, higher-quality coronavirus antibody tests have emerged that, among other uses, are beginning to give…